Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I) [Phase 1]

View source ↗

Summary

Phase I study assessing safety, tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in healthy adults; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye

Drugs mentioned

• cis-UCA eye drops (cis-urocanic acid)

Snippet

Sponsor: Laurantis Pharma, Ltd. | Conditions: Dry Eye | Phase 1 | Status: COMPLETED